Research programme: cancer therapeutics - e-Therapeutics/Nanjing
Latest Information Update: 09 Apr 2009
At a glance
- Originator e-Therapeutics; Nanjing KeyGen Biotech
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Cancer
Most Recent Events
- 10 Oct 2008 Investigation in Cancer in United Kingdom (unspecified route)